NCT06887348RecruitingPhase 4
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
Source: EU CTIS (euclinicaltrials.eu) · Last updated 29 Oct 2026
Brief summary (registry, in English)
To evaluate the long-term safety of patients treated with an RPx product and identify any delayed adverse event(s) related to treatment with an RPx product
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 41 (estimated)
- First submitted
- 7 Oct 2025
- Start date
- 16 Mar 2026
- Lead sponsor
- Replimune Group Inc.
- Diseases
- Melanoma, Liver and biliary tract cancer
- NCT number
- NCT06887348
- EU CT number
- 2025-521621-33-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 41
- 15 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other
- Cannot comply with the requirements of the study.
Who the study is looking for
- Patient has received at least 1 dose of an RPx product and has completed or discontinued participation in the parent study.
- Patient or patient’s legal guardian has provided signed informed consent (or assent), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (15)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Heidelberg AöR Coordinator of this site? Confirm its status | Heidelberg | Germany | Recruiting |
| LMU Klinikum Muenchen AöR Coordinator of this site? Confirm its status | Munich | Germany | Recruiting |
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| Hospital Clinic de Barcelona Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| Hospital Universitario 12 de Octubre Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| Hospital Clinico Universitario de Valencia Coordinator of this site? Confirm its status | Valencia | Spain | Recruiting |
| Centre Leon Berard Coordinator of this site? Confirm its status | Lyon | France | Recruiting |
| Institut Des Neurosciences De La Timone Coordinator of this site? Confirm its status | Marseille | France | Recruiting |
| Institut Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Recruiting |
| Hippokration Hospital Coordinator of this site? Confirm its status | Athens | Greece | Recruiting |
| Andreas Syngros Hospital Of Venereal And Dermatological Diseases Coordinator of this site? Confirm its status | Athens | Greece | Recruiting |
| Laiko General Hospital of Athens Coordinator of this site? Confirm its status | Athens | Greece | Recruiting |
| Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Coordinator of this site? Confirm its status | Cracow | Poland | Recruiting |
| Uniwersyteckie Centrum Kliniczne Coordinator of this site? Confirm its status | Gdansk | Poland | Recruiting |
| Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Coordinator of this site? Confirm its status | Warsaw | Poland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.